D. E. Shaw & Co. Inc. Buys 60,732 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

D. E. Shaw & Co. Inc. increased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 83.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 133,772 shares of the company's stock after purchasing an additional 60,732 shares during the period. D. E. Shaw & Co. Inc. owned approximately 0.13% of Dyne Therapeutics worth $3,152,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DYN. KBC Group NV raised its stake in Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after buying an additional 978 shares during the last quarter. Summit Investment Advisors Inc. grew its holdings in shares of Dyne Therapeutics by 9.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after acquiring an additional 721 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Dyne Therapeutics in the fourth quarter worth $257,000. Magnetar Financial LLC purchased a new stake in Dyne Therapeutics during the fourth quarter valued at $263,000. Finally, E Fund Management Co. Ltd. lifted its holdings in Dyne Therapeutics by 11.8% in the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock valued at $279,000 after acquiring an additional 1,249 shares during the period. Institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Trading Up 1.2%

Shares of DYN traded up $0.14 during trading hours on Thursday, reaching $11.90. 1,744,358 shares of the stock traded hands, compared to its average volume of 1,662,358. The company has a market cap of $1.35 billion, a P/E ratio of -3.34 and a beta of 1.19. The company's 50-day moving average price is $10.35 and its two-hundred day moving average price is $17.16. Dyne Therapeutics, Inc. has a 52-week low of $6.36 and a 52-week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on DYN shares. Guggenheim restated a "buy" rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. BMO Capital Markets initiated coverage on shares of Dyne Therapeutics in a research report on Wednesday, March 12th. They set an "outperform" rating and a $50.00 target price for the company. Chardan Capital reaffirmed a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Friday, May 9th. Piper Sandler dropped their price target on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research report on Friday, March 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $47.25.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.